Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001816 | 0.82 | TRPV1 (0.49) | TRPV1HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL6001093 | 0.82 | TRPV1 (0.49) | TRPV1HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL4864851 | 0.80 | TRPV1 (0.52) | TRPV1HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL4870857 | 0.77 | TRPV1 (0.54) | TRPV1HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL4728478 | 0.76 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL6001835 | 0.75 | TRPV1 (0.56) | ABCG2TRPV1PDE4B | |
| SCHEMBL10185784 | 0.75 | AURKA (0.58) | HTR2CHTR2AHTR2B | |
| SCHEMBL12426177 | 0.74 | HTR2C (0.55) | TRPV1PDE4BHTR2CHTR2AHTR2B | |
| SCHEMBL4871123 | 0.72 | TRPV1 (0.48) | TRPV1HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL5799780 | 0.71 | TRPV1 (0.69) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | OPRL1, AVPR1A, AVPR2 | ABCG2 359/4885TRPV1 5/4885PDE4B 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.